Table 1. Baseline characteristics of patients who encountered severe SAEs subsequent to SARS-CoV-2 vaccination, categorized by vaccination strategies.
| Total (N = 358) |
Vaccination strategy | P | |||
|---|---|---|---|---|---|
| Homo-mRNA (N = 220) |
Homo-viral vector (N = 75) |
Heterologous (N = 63) |
|||
| Age, median (IQR), y | 69 (57, 79) | 75 (53, 81) | 67 (62, 72) | 69 (62, 73) | 0.206a |
| Sex, N (%) | 0.062 | ||||
| Female | 131 (36.6) | 85 (38.6) | 19 (25.3) | 27 (42.9) | |
| Male | 227 (63.4) | 135 (61.4) | 56 (74.7) | 36 (57.1) | |
| Number of doses received, N (%) | <0.001 | ||||
| 2 | 240 (67.0) | 150 (68.2) | 75 (100) | 15 (23.8) | |
| 3 | 118 (33.0) | 70 (31.8) | 0 (0) | 48 (76.2) | |
| Vaccination site, N (%)c | <0.001b | ||||
| Medical institution | 245 (68.4) | 124 (56.4) | 63 (84.0) | 58 (92.1) | |
| Vaccination center | 93 (26.0) | 93 (42.3) | 0 (0) | 0 (0) | |
| Nursing hospital and facility | 10 (2.8) | 3 (1.4) | 4 (5.3) | 3 (4.8) | |
| Community health center | 10 (2.8) | 0 (0) | 8 (10.7) | 2 (3.2) | |
| CCI, N (%) | 0.465 | ||||
| ≤ 2 | 120 (33.5) | 79 (35.9) | 23 (30.7) | 18 (28.6) | |
| > 2 | 238 (66.5) | 141 (64.1) | 52 (69.3) | 45 (71.4) | |
| Comorbidities, N (%) | |||||
| Hypertension | 188 (52.5) | 111 (50.5) | 40 (53.3) | 37 (58.7) | 0.504 |
| Diabetes mellitus | 129 (36.0) | 69 (31.4) | 32 (42.7) | 28 (44.4) | 0.066 |
| Dyslipidemia | 87 (24.3) | 49 (22.3) | 23 (30.7) | 15 (23.8) | 0.341 |
| Heart failure | 8 (2.2) | 6 (2.7) | 0 (0) | 2 (3.2) | 0.406b |
| Arrhythmia | 22 (6.1) | 15 (6.8) | 4 (5.3) | 3 (4.8) | 0.861b |
| Ischemic heart disease | 38 (10.6) | 25 (11.4) | 4 (5.3) | 9 (14.3) | 0.199 |
| Stroke | 38 (10.6) | 21 (9.5) | 5 (6.7) | 12 (19.0) | 0.045 |
| Epilepsy | 7 (2.0) | 3 (1.4) | 2 (2.7) | 2 (3.2) | 0.487b |
| Parkinson’s disease | 4 (1.1) | 3 (1.4) | 0 (0) | 1 (1.6) | 0.636b |
| Dementia | 42 (11.7) | 24 (10.9) | 9 (12.0) | 9 (14.3) | 0.761 |
| Psychiatric disorder | 12 (3.4) | 7 (3.2) | 4 (5.3) | 1 (1.6) | 0.447b |
| Asthma | 17 (4.7) | 10 (4.5) | 2 (2.7) | 5 (7.9) | 0.357b |
| Thyroid disorder | 13 (3.6) | 4 (1.8) | 4 (5.3) | 5 (7.9) | 0.034b |
| Chronic liver disease | 7 (2.0) | 2 (0.9) | 3 (4.0) | 2 (3.2) | 0.103b |
| Chronic kidney disease | 20 (5.6) | 9 (4.1) | 3 (4.0) | 8 (12.7) | 0.048b |
| Benign prostatic hyperplasia | 17 (4.7) | 12 (5.5) | 3 (4.0) | 2 (3.2) | 0.827b |
| Cancer | 22 (6.1) | 12 (5.5) | 5 (6.7) | 5 (7.9) | 0.706b |
Note: Age is displayed as median (interquartile range), while categorical variables are represented as N (%).
Abbreviations: SAEs, serious adverse events; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; Homo-mRNA, Homologous mRNA; Homo-viral vector, Homologous viral vector; IQR, interquartile range; CCI, Charlson Comorbidity Index.
aKruskal-Wallis H test was employed for the analyses.
bFisher’s exact test was employed for the analyses.
cThe vaccination site with the nearest temporal proximity to the adverse event was selected for the analysis.